FDA warns J&J vaccine plant in South Korea following 2024 inspectionnews2025-09-23T18:54:28+00:00September 23rd, 2025|Endpoints News|
FDA’s move to update old GSK drug for autism raises questions on dose, supply and datanews2025-09-23T18:23:04+00:00September 23rd, 2025|Endpoints News|
Aera Therapeutics jumps into in vivo CAR-T race with trial planned for 2026news2025-09-23T18:00:33+00:00September 23rd, 2025|Endpoints News|
Lilly sets aside $6.5B for new Texas site to make its obesity pill news2025-09-23T17:00:55+00:00September 23rd, 2025|Endpoints News|
Neurocrine details Phase 2 results for depression drug news2025-09-23T15:24:29+00:00September 23rd, 2025|Endpoints News|
Bristol Myers said its next-gen multiple myeloma drug cut rates of detectable cancer. Will it get FDA approval?news2025-09-23T15:16:15+00:00September 23rd, 2025|Endpoints News|
Invivo aims to raise €100M for fourth fund; SEED Therapeutics gets $30Mnews2025-09-23T14:25:11+00:00September 23rd, 2025|Endpoints News|
Why Doximity wants to be the Bloomberg Terminal for doctorsnews2025-09-23T12:30:46+00:00September 23rd, 2025|Endpoints News|
FDA hands Scholar Rock a CRL for spinal muscular atrophy drugnews2025-09-23T11:25:22+00:00September 23rd, 2025|Endpoints News|
Eli Lilly sells New Jersey site to Celltrion for $330Mnews2025-09-23T10:59:40+00:00September 23rd, 2025|Endpoints News|
